Signal2026-07-17
ClinicalTrials.gov

[PHASE1] FH-WT1-E50 TCR T Cells With Azacitidine for the Treatment of Minimal Residual Disease Positive Acute Myeloid Leukemia

Open primary sourceRead on Substack